Jeffrey Hansen, MD
Family Medicine · Nampa, IDNPI 1932199981
Payments from drug & device makers
Across 100 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$222
- Exact Sciences$123
- Otsuka America Pharmaceutical, Inc.$115
- Bayer$112
- Novo Nordisk$91
- AbbVie$90
- plus $892 from 23 others
What the payments were for
- Food & beverage$1,646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $222 |
| Exact Sciences | 7 | $123 |
| Otsuka America Pharmaceutical, Inc. | 6 | $115 |
| Bayer | 7 | $112 |
| Novo Nordisk | 6 | $91 |
| AbbVie(2 entities) | 5 | $90 |
| Sanofi-aventis U.S. LLC | 5 | $89 |
| Johnson & Johnson | 7 | $88 |
| Vanda Pharmaceuticals Inc. | 4 | $84 |
| Sunovion Pharmaceuticals Inc. | 1 | $80 |
| AstraZeneca | 6 | $76 |
| Boehringer Ingelheim | 4 | $59 |
| Merck | 4 | $59 |
| Pfizer | 3 | $44 |
| GSK | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Lilly USA, LLC | 2 | $29 |
| Corium, LLC | 2 | $26 |
| Astellas Pharma US Inc | 2 | $23 |
| Antares Pharma, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Abbott | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,646 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $62,368 |
| OzempicSemaglutide | 32 | $32,579 |
| OxycontinOxycodone Hcl | 57 | $26,373 |
| FarxigaDapagliflozin Propanediol | 68 | $21,842 |
| JanuviaSitagliptin Phosphate | 38 | $11,945 |
| MyrbetriqMirabegron | 29 | $10,244 |
| XareltoRivaroxaban | 30 | $9,882 |
| Potassium Chloride | 113 | $8,729 |
| JardianceEmpagliflozin | 19 | $6,428 |
| Duloxetine Hcl | 70 | $4,398 |
| Gabapentin | 190 | $3,432 |
| Bumetanide | 33 | $2,975 |
| Levothyroxine Sodium | 177 | $2,398 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,324 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $2,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $62,368187 claims |
| Novo NordiskOzempic | $91 | $32,57932 claims |
| AstraZenecaFarxiga | $76 | $21,84268 claims |
| MerckJanuvia | $59 | $11,94538 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $10,24429 claims |
| Johnson & JohnsonXarelto | $88 | $9,88230 claims |
| Boehringer IngelheimJardiance | $59 | $6,42819 claims |
| Lilly USA, LLCOlanzapine | $29 | $76615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 803 family medicine providers in Idaho.
Other family medicine in Nampa
- Bryan PogueNampa$8K
- Trent GilesNampa$8K
- Kindra GallowayNampa$6K
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- William LaitinenMiddleton$1.1M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.